CyberKnife Spinal Tumor Treatments Increase by 56 Percent
Success of Non-Invasive Procedure Chronicled in the Journal Spine
SUNNYVALE, Calif., Feb. 20 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced clinical data that shows use of its CyberKnife(R) Robotic Radiosurgery System in the treatment of spinal tumors has increased by 56 percent between December 2005 and December 2006. Success of this non-invasive procedure, which avoids potential damage to the spinal cord, is further validated by a study of 500 spinal tumor patients. The study results were published in the January 15 issue of the journal Spine.
Tumors in the spine, particularly metastatic tumors, are difficult to remove surgically and are challenging to treat with radiation because of their close proximity to the spinal cord. Damage to the spinal cord can result in loss of movement, feeling or even paralysis.
"Because the spine moves, there is a high risk with treatments such as those delivered by radiation therapy devices that the spinal cord could move into the radiation field," said Eric P. Lindquist, senior vice president and chief marketing officer at Accuray." With Accuray's CyberKnife System, which tracks tumor and patient movement during treatment, the risk of damage to surrounding healthy tissue and critical structures, like the spinal cord, is minimized."
Accuray is a pioneer in the radiosurgical treatment of spinal tumors. The company's CyberKnife Xsight(TM) Spine Tracking System is a breakthrough in tracking technology. It is the first and only system that uses the internal anatomy to directly track tumors with radiosurgical precision without the need for external frames or implanted fiducials. The Xsight System registers unique non-rigid and bony anatomy landmarks to track, detect and correct for the movement of the spine in real-time throughout the treatment. It allows doctors to deliver high doses of radiation with sub-millimeter accuracy while avoiding damage to healthy tissue.
"We've had tremendous success with the CyberKnife System in treating patients with complex spinal tumors," said Dr. Peter Gerszten, lead author of the study. "The results of our study demonstrate the CyberKnife System's effectiveness in controlling tumor progression and minimizing any associated side effects."
The study, titled "Radiosurgery for Spinal Metastases: Clinical Experience in 500 Cases From a Single Institution," was conducted at the University of Pittsburgh Medical Center in Pittsburgh, Pa., and included 500 patients ages 18 to 85 with tumors in all parts of the spine.
"When I learned I had a tumor on my spinal cord, doctors told me that without surgery I would be paraplegic but that the extremely delicate and risky surgery would involve removing ribs and intestines," said Carol Alfaro, a spinal tumor patient. "I opted for treatment with the CyberKnife System and with just three, pain-free outpatient visits, I had my life back."
By eliminating the need for invasive surgery, the CyberKnife System allows patients to recover more quickly, experience fewer complications and immediately resume regular daily activities after treatment.
About the CyberKnife(R) Robotic Radiosurgery System
The CyberKnife System represents the next generation of radiosurgery systems, combining continuous image-guidance technology with a compact linear accelerator that has the flexibility to move in three dimensions according to the treatment plan. This combination, which is referred to as intelligent robotics, extends the benefits of radiosurgery to the treatment of tumors anywhere in the body. The CyberKnife System autonomously tracks, detects and corrects for tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation typically with sub-millimeter accuracy.
Accuray Incorporated, based in Sunnyvale, Calif., is a global leader in the field of radiosurgery. Its CyberKnife System is the world's first and only commercially available intelligent robotic radiosurgery system designed to treat tumors anywhere in the body, typically with sub-millimeter accuracy. To date, it is estimated that the CyberKnife System has treated more than 20,000 patients worldwide. For more information, please visit www.accuray.com .
Safe Harbor Statement
The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors, including factors set forth in the Company's prospectus. A final prospectus for the offering may be obtained from J.P. Morgan Securities Inc., Prospectus Library, 4 Chase Metrotech Center, CS Level, Brooklyn, NY 11245, and UBS Investment Bank, Prospectus Department, 299 Park Avenue, New York, NY 10171.
NOTE: Accuray, the Accuray logo, CyberKnife, Synchrony, Xsight and RoboCouch are among trademarks or registered trademarks of Accuray Incorporated.
SOURCE Accuray Incorporated
CONTACT: Susan Lehman of Rockpoint Public Relations, +1-510-832-6006, or email@example.com, for Accuray; or Stephanie Tomei, Accuray PR Manager, +1-408-789-4234, or firstname.lastname@example.org
Web site: www.accuray.com